PURPOSE: In this work, we investigate prodrug and enhancer approaches for transdermal and topical delivery of antiviral drugs belonging to the 2,6-diaminopurine acyclic nucleoside phosphonate (ANP) group. Our question was whether we can differentiate between transdermal and topical delivery, i.e., to control the delivery of a given drug towards either systemic absorption or retention in the skin. METHODS: The in vitro transdermal delivery and skin concentrations of seven antivirals, including (R)- and (S)-9-[2-(phosphonomethoxy)propyl]-2,6-diaminopurine (PMPDAP), (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine ((S)-HPMPDAP), its 8-aza analog, and their cyclic and hexadecyloxypropyl (HDP) prodrugs, was investigated with and without the penetration enhancer dodecyl-6-(dimethylamino)hexanoate (DDAK) using human skin. RESULTS: The ability of ANPs to cross the human skin barrier was very low (0.5-1.4 nmol/cm(2)/h), and the majority of the compounds were found in the stratum corneum, the uppermost skin layer. The combination of antivirals and the penetration enhancer DDAK proved to be a viable approach for transdermal delivery, especially in case of (R)-PMPDAP, an anti-HIV effective drug (30.2 ± 2.3 nmol/cm(2)/h). On the other hand, lysophospholipid-like HDP prodrugs, e.g., HDP-(S)-HPMPDAP, reached high concentrations in viable epidermis without significant systemic absorption. CONCLUSIONS: By using penetration enhancers or lysolipid prodrugs, it is possible to effectively target systemic diseases by the transdermal route or to target cutaneous pathologies by topical delivery.

Skin Barrier Research Group Charles University Prague Faculty of Pharmacy in Hradec Králové Heyrovského 1203 50005 Hradec Králové Czech Republic

Zobrazit více v PubMed

Eur J Pharm Biopharm. 2008 Jun;69(2):597-604 PubMed

Curr Opin HIV AIDS. 2012 Nov;7(6):520-5 PubMed

Nat Biotechnol. 2008 Nov;26(11):1261-8 PubMed

Pharm Res. 2009 Apr;26(4):811-21 PubMed

Adv Drug Deliv Rev. 2004 Mar 27;56(5):603-18 PubMed

J Control Release. 2013 Jan 28;165(2):91-100 PubMed

Pharm Res. 2006 Dec;23(12):2729-47 PubMed

Antiviral Res. 2009 Dec;84(3):254-9 PubMed

Antiviral Res. 1995 Dec;28(4):343-57 PubMed

Biochem Biophys Res Commun. 1996 Feb 15;219(2):337-41 PubMed

Antiviral Res. 2011 Nov;92(2):277-91 PubMed

Antimicrob Agents Chemother. 2005 Dec;49(12):4843-52 PubMed

Antivir Chem Chemother. 2012 May 14;22(5):181-203 PubMed

J Med Chem. 2010 Oct 14;53(19):6825-37 PubMed

Pharm Res. 2011 Dec;28(12):3105-15 PubMed

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):198-203 PubMed

Bioorg Med Chem. 2006 Dec 1;14(23):7671-80 PubMed

Antimicrob Agents Chemother. 1993 Feb;37(2):332-8 PubMed

Eur J Pharm Sci. 2001 Sep;14(2):101-14 PubMed

J Med Chem. 1996 Sep 27;39(20):4073-88 PubMed

Eur J Pharm Biopharm. 2008 Nov;70(3):901-7 PubMed

Nat Rev Drug Discov. 2005 Nov;4(11):928-40 PubMed

Antimicrob Agents Chemother. 2007 Dec;51(12):4410-9 PubMed

Bioorg Med Chem. 2013 Mar 1;21(5):1199-208 PubMed

Bioorg Med Chem. 2006 Dec 1;14(23):7681-7 PubMed

Curr Pharm Des. 2003;9(31):2567-92 PubMed

MMWR Recomm Rep. 2003 Feb 21;52(RR-4):1-28 PubMed

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4688-93 PubMed

Antimicrob Agents Chemother. 1989 Sep;33(9):1482-6 PubMed

Antiviral Res. 2009 May;82(2):A84-98 PubMed

Antimicrob Agents Chemother. 2002 Nov;46(11):3356-61 PubMed

Curr Med Chem. 2005;12(19):2273-91 PubMed

J Control Release. 2011 Mar 10;150(2):164-70 PubMed

Biochem Pharmacol. 2011 Jul 15;82(2):99-109 PubMed

Antimicrob Agents Chemother. 1991 Nov;35(11):2440-3 PubMed

Antimicrob Agents Chemother. 1995 Mar;39(3):746-9 PubMed

Esters of terpene alcohols as highly potent, reversible, and low toxic skin penetration enhancers

Galactosyl Pentadecene Reversibly Enhances Transdermal and Topical Drug Delivery

Dodecyl Amino Glucoside Enhances Transdermal and Topical Drug Delivery via Reversible Interaction with Skin Barrier Lipids